Evidence map›Paper›PMID 40713037›Full record

ArticleBMJ open2025

Beneficial value of [

Nicole E Billingy, Cornelia A Verberkt, Idris Bahce, Marloes J Hassing, Joran Schoorlemmer, Merve Sarioglu, Suresh Senan, Erik H J G Aarntzen, Emile F I Comans, Wietske Kievit and 7 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06082492 (The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06082492 narecruitingnot on this map

The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients: the NVALT31-PET Study

TypeinterventionalSponsorRadboud University Medical CenterRan2024 to 2029Enrolled690ConditionsStage III Non-small Cell Lung CancerArms18F FDG PET/CT, CT scan
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nicole E Billingy *IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands nicole.billingy@radboudumc.nl.ORCID http://orcid.org/0000-0002-3590-4961
Cornelia A Verberkt *IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Idris BahceDepartment of Pulmonary Medicine, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Marloes J HassingIQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Joran SchoorlemmerIQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Merve SariogluIQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Suresh SenanDepartment of Radiation Oncology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Erik H J G AarntzenDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Emile F I ComansDepartment of Radiology & Nuclear Medicine, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Wietske KievitIQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Steven TeerenstraIQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
Colin JacobsDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
Astrid KeijserDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Michel M van den HeuvelDepartment of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Annemarie Becker-Commissaris *Department of Pulmonary Medicine, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
Iris Walraven *IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands.
The NVALT31-PET Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with stage III non-small cell lung cancer (NSCLC) are at high risk of developing post-treatment recurrences (50-78%) during follow-up. As more effective treatments are now available, especially for patients with oligometastatic disease, earlier detection of recurrences may prolong survival and health-related quality of life (HRQOL). With the use of 2'-deoxy-2'-[ METHODS AND ANALYSIS: In this multicentre randomised controlled clinical trial, 690 patients with stage III NSCLC (8th edition International Association for the Study of Lung Cancer (IASLC) Tumor, Nodes, Metastasis (TNM) classification) who completed curative intended treatment and started follow-up care (which may include adjuvant therapy) will be randomised 1:1 to either the intervention ([ ETHICS AND DISSEMINATION: The study protocol has been approved by the Medical Ethical Committee of the Radboudumc and review boards of all participating centres. Written informed consent will be obtained from all participants. Study results will be published in international peer-reviewed scientific journals and presented at relevant scientific conferences. Data will be published in a data repository or other online data archive. TRIAL REGISTRATION NUMBER: NCT06082492.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyCost-Benefit AnalysisFemaleFluorodeoxyglucose F18Follow-Up StudiesHumansMaleMulticenter Studies as TopicNeoplasm StagingQuality of LifeRadiopharmaceuticalsRandomized Controlled Trials as TopicFluorodeoxyglucose F18RadiopharmaceuticalsDiagnostic ImagingONCOLOGYRespiratory tract tumours

Identifiers

PMID40713037
PMCPMC12306341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.